MMED MiniMed Group, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2062583 · Fiscal year ends 12/31
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-50.0%
TTM EPS YoY-49.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-8.6%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.3%
Debt / equity0.00x
Current ratio1.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-07-31 | 2026Q4*2026-04-24 | 2026Q32026-01-23 | 2026Q2*2025-10-24 | 2026Q12025-07-25 | 2025Q4*2025-04-25 | 2025Q32025-01-24 | 2025Q2*2024-10-25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $843.00M | $837.00M | $790.00M | — | $723.00M | $724.00M | $687.00M | — |
| Cost of revenue | $378.00M | $357.00M | $428.00M | — | $314.00M | $318.00M | $292.00M | — |
| Gross profit | $465.00M | $480.00M | $362.00M | — | $409.00M | $405.00M | $395.00M | — |
| R&D expense | $115.00M | $99.00M | $114.00M | — | $125.00M | $107.00M | $112.00M | — |
| SG&A expense | $312.00M | $299.00M | $309.00M | — | $283.00M | $276.00M | $268.00M | — |
| Operating income | $5.00M | -$93.00M | -$100.00M | — | -$13.00M | -$148.00M | $21.00M | — |
| Pretax income | $4.00M | -$92.00M | -$99.00M | — | -$13.00M | -$148.00M | $21.00M | — |
| Income tax | $4.00M | $93.00M | $12.00M | — | $3.00M | $21.00M | $28.00M | — |
| Net income | $0 | -$185.00M | -$119.00M | -$5.00M | -$19.00M | -$172.00M | -$10.00M | -$5.00M |
| EBITDA | $46.00M | -$54.00M | — | — | $26.00M | -$110.00M | — | — |
| EPS (basic) | 0.00 | — | -0.47 | — | -0.08 | — | -0.04 | — |
| EPS (diluted) | 0.00 | — | -0.47 | — | -0.08 | — | -0.04 | — |
| Weighted avg. shares (diluted) | 281.00M | — | 252.81M | — | 252.80M | — | 252.81M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $207.00M | $298.00M | $10.00M | — | $9.00M | $11.00M | $10.00M | — |
| Receivables | $180.00M | $200.00M | $653.00M | — | — | $570.00M | — | — |
| Inventory | $356.00M | $341.00M | $408.00M | — | — | $311.00M | — | — |
| Current assets | $1.42B | $1.35B | $1.11B | — | — | $939.00M | — | — |
| PP&E, net | $736.00M | $711.00M | $701.00M | — | — | $706.00M | — | — |
| Goodwill | $2.25B | $2.26B | $2.26B | — | — | $2.25B | — | — |
| Intangibles | $100.00M | $107.00M | $113.00M | — | — | $132.00M | — | — |
| Total assets | $4.72B | $4.63B | $4.34B | — | — | $4.20B | — | — |
| Current liabilities | $782.00M | $702.00M | $696.00M | — | — | $710.00M | — | — |
| Total liabilities | $1.10B | $1.02B | $881.00M | — | — | $871.00M | — | — |
| Shareholders' equity | $3.62B | $3.61B | $3.46B | $3.56B | $3.54B | $3.33B | $3.48B | $3.46B |
| Shares outstanding | 281.21M | 280.82M | — | — | — | 0 | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$49.00M | -$170.00M | — | — | -$141.00M | $83.00M | — | — |
| Capital expenditure | $41.00M | $56.00M | — | — | $53.00M | $57.00M | — | — |
| Free cash flow | -$90.00M | -$226.00M | — | — | -$194.00M | $26.00M | — | — |
| Investing cash flow | -$41.00M | -$56.00M | — | — | -$63.00M | -$57.00M | — | — |
| Financing cash flow | $0 | $512.00M | — | — | $202.00M | -$25.00M | — | — |
| Depreciation & amortization | $41.00M | $39.00M | — | — | $39.00M | $38.00M | — | — |
| Stock-based compensation | $10.00M | $8.00M | $11.00M | — | $9.00M | $9.00M | $11.00M | — |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.